PMID- 8380295
OWN - NLM
STAT- MEDLINE
DCOM- 19930202
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 11
IP  - 1
DP  - 1993 Jan
TI  - Treatment outcomes in patients less than 2 years of age with small, stage I, 
      favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.
PG  - 91-5
AB  - PURPOSE: Retrospective analyses were performed to determine the effect of tumor 
      weight and therapy modifications on outcome in patients less than 2 years of age 
      with stage I favorable-histology Wilms' tumors. PATIENTS AND METHODS: The 4-year 
      relapse-free and overall survival percentages for patients randomized to 
      different treatment regimens in National Wilms' Tumor Studies (NWTS)-1, -2, and 
      -3 were calculated and compared. RESULTS: The 4-year relapse-free survival 
      percentages of patients whose specimen weight was less than 550 g were found to 
      be 89.1% on NWTS-1, 96.0% on NWTS-2, and 93.2% on NWTS-3. There was no evidence 
      that the relapse-free survival of these patients had improved over time (P value 
      for trend = .99). The 4-year relapse-free survival percentage for similar age and 
      stage patients whose specimen weight was 550 g or greater was significantly 
      poorer than that of patients with smaller tumors (P = .02). CONCLUSION: Changes 
      in the NWTS treatment regimens over a period of more than 20 years have not 
      improved on the excellent prognosis of patients who are less than 2 years of age 
      at diagnosis and who have a stage I, favorable-histology Wilms' tumor with 
      specimen weight less than 550 g. These data could be used as the basis for a 
      future trial in which a subgroup of such patients is treated with nephrectomy 
      only.
FAU - Green, D M
AU  - Green DM
AD  - Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY 14263-0001.
FAU - Breslow, N E
AU  - Breslow NE
FAU - Beckwith, J B
AU  - Beckwith JB
FAU - Takashima, J
AU  - Takashima J
FAU - Kelalis, P
AU  - Kelalis P
FAU - D'Angio, G J
AU  - D'Angio GJ
LA  - eng
GR  - CA-42326/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 1CC1JFE158 (Dactinomycin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Combined Modality Therapy
MH  - Dactinomycin/therapeutic use
MH  - Humans
MH  - Infant
MH  - Kidney Neoplasms/pathology/*therapy
MH  - Neoplasm Staging
MH  - Nephrectomy
MH  - Recurrence
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Wilms Tumor/pathology/*therapy
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1200/JCO.1993.11.1.91 [doi]
PST - ppublish
SO  - J Clin Oncol. 1993 Jan;11(1):91-5. doi: 10.1200/JCO.1993.11.1.91.